VVD-065
- Generic Name
- VVD-065
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Vividion Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT05954312
- Locations
- 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath